Jikei University School of Medicine, Tokyo, Japan
Gynecological cancer is less frequent compared to breast or colorectal cancer and there are lots of histological variants making treatment modality more complex particularly in ovarian cancer. Twenty-nine countries developed their own gynecologic oncology group to promote and conduct high quality clinical trials in order to improve outcomes.To set up a significant clinical trial, accumulation of certain number of cases is needed to fulfill the statistically assured sample size. International collaboration is further promoted among those countries and the biggest group is the Gynecological Cancer Inter Group comprising all regional 29 groups. This enables to achieve the collection of rare tumor and could establish the evidence-based new treatment strategy through a strong sense of common purpose and mutual recognition. While the international clinical trials occasionally give rise to its specific issues in regulatory functions on ethnicity and cultural geographic and clinical accommodation. Examples of international clinical trials successfully establishing worldwide standard and their issues of regulatory functions will be presented.